RPRX vs. CG, BEKE, SHG, BAM, L, CRBG, AER, TPG, AEG, and NTRS
Should you be buying Royalty Pharma stock or one of its competitors? The main competitors of Royalty Pharma include The Carlyle Group (CG), KE (BEKE), Shinhan Financial Group (SHG), Brookfield Asset Management (BAM), Loews (L), Corebridge Financial (CRBG), AerCap (AER), TPG (TPG), Aegon (AEG), and Northern Trust (NTRS). These companies are all part of the "finance" sector.
The Carlyle Group (NASDAQ:CG) and Royalty Pharma (NASDAQ:RPRX) are both large-cap finance companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation.
In the previous week, The Carlyle Group had 31 more articles in the media than Royalty Pharma. MarketBeat recorded 34 mentions for The Carlyle Group and 3 mentions for Royalty Pharma. The Carlyle Group's average media sentiment score of 1.10 beat Royalty Pharma's score of 0.57 indicating that Royalty Pharma is being referred to more favorably in the news media.
The Carlyle Group has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500.
The Carlyle Group received 262 more outperform votes than Royalty Pharma when rated by MarketBeat users. However, 68.10% of users gave Royalty Pharma an outperform vote while only 57.06% of users gave The Carlyle Group an outperform vote.
Royalty Pharma has higher revenue and earnings than The Carlyle Group. The Carlyle Group is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
55.9% of The Carlyle Group shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 27.2% of The Carlyle Group shares are held by company insiders. Comparatively, 18.7% of Royalty Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
The Carlyle Group currently has a consensus price target of $44.25, indicating a potential upside of 7.77%. Royalty Pharma has a consensus price target of $46.75, indicating a potential upside of 64.55%. Given The Carlyle Group's stronger consensus rating and higher probable upside, analysts plainly believe Royalty Pharma is more favorable than The Carlyle Group.
Royalty Pharma has a net margin of 48.22% compared to Royalty Pharma's net margin of -23.04%. The Carlyle Group's return on equity of 26.93% beat Royalty Pharma's return on equity.
The Carlyle Group pays an annual dividend of $1.40 per share and has a dividend yield of 3.4%. Royalty Pharma pays an annual dividend of $0.84 per share and has a dividend yield of 3.0%. The Carlyle Group pays out -78.2% of its earnings in the form of a dividend. Royalty Pharma pays out 44.4% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. The Carlyle Group has increased its dividend for 2 consecutive years and Royalty Pharma has increased its dividend for 4 consecutive years. The Carlyle Group is clearly the better dividend stock, given its higher yield and lower payout ratio.
Summary
Royalty Pharma beats The Carlyle Group on 12 of the 21 factors compared between the two stocks.
Get Royalty Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Royalty Pharma Competitors List
Related Companies and Tools
